PT-141 (bremelanotide) is a synthetic peptide derived from alpha-MSH, investigated for its potential effect on the central regulation of sexual behavior, especially in women with low sexual desire. The mechanism of action is not related to the hormonal system, but acts directly on brain receptors.
This product is intended for laboratory and research purposes only. It is not intended for human consumption or veterinary use.
The content below is for informational and scientific research purposes only.
What is PT-141 (Bremelanotide)?
PT-141 is a synthetic peptide derived from the hormone alpha-MSH (alpha-melanocyte stimulating hormone), which binds primarily to the melanocortin receptors MC3R and MC4R in the central nervous system. The scientific interest in this substance stems from its ability to influence sexual behavior and desire without interfering with the vascular system. Unlike PDE5 inhibitors (e.g. sildenafil), PT-141 acts centrally - affecting motivation and the psychological component of libido.
How it works
PT-141 activates melanocortin receptors (especially MC4R) in the brain, which are responsible for sexual behavior and arousal. It acts directly on the CNS (hypothalamus), thereby stimulating libido and sexual motivation. It does not affect estrogen, progesterone, or testosterone levels. Interestingly, this effect has been observed mainly in women with hypoactive sexual desire disorder (HSDD), but the substance is also being studied in men.
Researched effects and interesting facts
-
Stimulation of sexual behavior: Significant effects in women with HSDD, approved by the FDA for medical use under the trade name Vyleesi.
-
Effects on central motivation: Acts independently of peripheral vascular mechanisms.
-
Possible effects on mood: Improvements in mood and emotional response have been observed in some research.
-
Effects in men: Potential improvement of erectile function in men with sexual dysfunction.
Dosage in studies
Study: Randomized double-blind study (FDA, USA)
Dose: 1.75 mg
Administration form: Subcutaneous
Frequency: Administered as needed (approximately 45 minutes before intercourse)
Duration: 8 weeks
The doses listed are for informational purposes only and do not constitute a recommendation for use.
Possible side effects
- nausea
- facial redness
- headache
- less often increased blood pressure or fatigue
Resources
- Brevard, M. et al. (2019). Bremelanotide for hypoactive sexual desire disorder. J Sex Med .
- FDA.gov. Vylesi - Approval History and Labeling.
- Carroll, B. et al. (2016). MC4R agonists and sexual behavior. Endocrinology .
This article is for scientific informational purposes only. It does not contain recommendations for human or veterinary use.
Sale
